Clinical trial NCT04527250: A Study of the Relative Bioavailability of ASC41 in Healthy Subjects
Official title: Comparison of the Pharmacokinetic Parameters of ASC41, a Randomized, Double-blind, Placebo-controlled in Healthy Subjects After Single and Multiple Doses
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Ascletis Pharma Inc
Sponsor class: INDUSTRY
Collaborators: name: Hunan Provincial People's Hospital
First posted: 2020-08-26
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of this study is to compare the pharmacokinetic parameters of ASC41 in healthy subjects after single and multiple oral dosing.

Detailed description: The purpose of this study was to evaluate the tolerability, safety pharmacokinetics and pharmacodynamic (biomarkers) of ASC41 tables in a randomized, double-blind, placebo-controlled single- and multiple-dose phase I clinical trial in healthy subjects the study. The effects of ASC41 on LDL-C and other lipid parameters (TG, TC, HDL-C, etc.) will be observed after repeated administration of ASC41 in healthy subjects.

Eligibility criteria: Inclusion Criteria:

* 1. Age 18-45 (including boundary value). 2. Male weight ≥ 50kg, female weight ≥ 45kg;BMI ranges from 19 to 30kg/m2 (boundary value included).

  3. She is of childbearing potential and is non-pregnant and willing to use adequate contraception from screening (within 30days from the first administration)until one month after the End of Study visit.

  4. The pregnancy test of female subjects during the screening period is negative.

  5. During the screening period, fasting low-density lipoprotein cholesterol (110mg/dl \< fasting (LDL-C) \< 190mg/ dL.

  6. Those who voluntarily sign the informed consent.

Exclusion Criteria:

* 1. Patients with a history of thyroid disease or intolerance to beta blockers or abnormal thyroid function indicators during screening; 2. Previous history of fainting, fainting needle or fainting blood for unknown reasons.

  3. Previous liver disease, or ALT, ASL and direct bilirubin in screening period exceed the normal range.

  4. Hepatitis B surface antigen (HBsAg), Hepatitis C virus antibody (HCV Ab), HIV antibody (HIV Ab) and syphilis antibody are tested positive.

  5. People who have taken special diet (including carambola, dragon fruit, mango, grapefruit, orange, etc.) or drunk alcohol, or had strenuous exercise, or other factors affecting drug absorption, distribution, metabolism, and excretion within 2 weeks before taking the study drug.

  6. Heavy smokers (14 units of alcohol per week: 1 unit = 285 mL beer, or 25 mL spirits, or 100 mL wine;Smoking daily ≥ 5 sticks) and no smoking or alcohol prohibition during the study period.

  7. Ingesting chocolate, any food or drink containing caffeine or xanthine in the 24 hours prior to taking the study drug.

  8. Patients who had donated blood or lost blood of more than 400ml within 3 months before taking the study drug.

  9. Those who have participated in other clinical trials and received study drug treatment within 3 months before taking study drug.

  10. In addition to the above, the researchers judge that the participants are not suitable to participate in this clinical trial.

Primary outcomes:
measure: Evaluation of the safety and tolerability of ASC41 in healthy volunteers
timeFrame: Up to 32 days
Secondary outcomes:
measure: Cmax of ASC41
timeFrame: On Day 1,2,3,4 after single doses and On Day 1,2,3,4 after multiple doses, respectively. The entire study will last up to 32 days.
measure: Tmax of ASC41
timeFrame: On Day 1,2,3,4 after single doses and On Day 1,2,3,4 after multiple doses, respectively. The entire study will last up to 32 days.
measure: AUC of ASC41
timeFrame: On Day 1,2,3,4 after single doses and On Day 1,2,3,4 after multiple doses, respectively. The entire study will last up to 32 days.
measure: t1/2 of ASC41
timeFrame: On Day 1,2,3,4 after single doses and On Day 1,2,3,4 after multiple doses, respectively. The entire study will last up to 32 days.
measure: CL/F of ASC41
timeFrame: On Day 1,2,3,4 after single doses and On Day 1,2,3,4 after multiple doses, respectively. The entire study will last up to 32 days.
measure: Vd/F of ASC41
timeFrame: On Day 1,2,3,4 after single doses and On Day 1,2,3,4 after multiple doses, respectively. The entire study will last up to 32 days.
Other outcomes:
Locations:
city: Changsha
country: China
facility: Hunan provincial people's hospital
state: Hunan
Study officials:
References: